The relationship between serum Trx1, PDCD4, AQP4 expression and cognitive function in patients with Parkinson‘s disease

doi:10.11958/20241632

Abstract

Abstract:

Objective To explore the relationship between serum thioredoxin 1 (Trx1), programmed cell death factor 4 (PDCD4), aquaporin 4 (AQP4) expression and cognitive function in patients with Parkinson's disease (PD). Methods A total of 145 PD patients (PD group) were selected as the study subjects, and patients were divided into the cognition impairment (CI) group 43 cases and the no CI group (102 cases) according to the mini-mental state examination (MMSE). Another 105 healthy subjects in the same period were taken as the control group. General patient data were collected and analyzed. The serum expression of Trx1, PDCD4 and AQP4 were detected by ELISA. The correlation between serum levels of Trx1, PDCD4 and AQP4 in PD patients and CI score were analyzed by Pearson method. Multivariate Logistic regression was used to analyze influencing factors of CI in PD patients. The predictive values of serum Trx1, PDCD4 and AQP4 levels for the occurrence of CI in PD patients were analyzed by receiver operating characteristic (ROC) curve. Results Serum levels of Trx1 and AQP4 were lower in the PD group than those of the control group, and PDCD4 was higher in the PD group than that of the control group (P<0.05). In the CI group, PD duration and PDCD4 levels were higher than those of the no CI group (P<0.05), and BMI, years of education, MMSE score, MoCA score, Trx1 and AQP4 were lower than those in the no CI group (P<0.05). In the PD group, serum Trx1 and AQP4 levels were positively correlated with MMSE and MoCA scores, and serum PDCD4 levels were negatively correlated with MMSE and MoCA scores (P<0.05). The long course of disease and increased PDCD4 levels were risk factors for CI in PD patients, while increased Trx1 and AQP4 levels were protective factors for CI in PD patients (P<0.05). Serum Trx1, PDCD4, AQP4 levels and the combined AUC for predicting CI in PD patients were 0.820, 0.741, 0.831 and 0.932, respectively, and the combined prediction was better than the respective prediction alone. Conclusion Serum Trx1, AQP4 and PDCD4 are closely related to cognitive function, and the combination of the three has high predictive value for CI in PD patients.

Key words: Parkinson disease, cognitive dysfunction, thioredoxins, apoptosis regulatory proteins, aquaporin 4, programmed cell death factor 4

CLC Number:

R742

Figures/Tables 6

References 22

[1]	ÖZKAN A, BÜLBÜL M, DERIN N, et al. Neuropeptide-S affects cognitive impairment and depression-like behavior on MPTP induced experimental mouse model of Parkinson's disease[J]. Turk J Med Sci, 2021, 51(6):3126-3135. doi:10.3906/sag-2105-74.
[2]	童宁, 程蕊, 孙荣芝. 帕金森病患者血压变化与认知功能的研究进展[J]. 中国实用神经疾病杂志, 2024, 27(9):1179-1183.
	TONG N, CHENG R, SUN R Z. Progress in blood pressure changes and cognitive function in patients with Parkinson's disease[J]. Chinese Journal of Practical Neurological Diseases, 2024, 27(9):1179-1183. doi:10.12083/SYSJ.240432.
[3]	李敏, 黎玉环, 罗洁, 等. 帕金森病患者血清ESM-1、ET-1表达与认知功能的关系[J]. 疑难病杂志, 2022, 21(11):1124-1128.
	LI M, LI Y H, LUO J, et al. The relationship between serum ESM-1 and ET-1 expression and cognitive function in patients with Parkinson's disease[J]. Journal of Difficult Diseases, 2022, 21(11):1124-1128. doi:10.3969/j.issn.1671-6450.2022.11.002.
[4]	姬莉, 杨宁, 刘卫国, 等. 老年帕金森病患者自主神经功能与认知功能的相关分析[J]. 中国现代神经疾病杂志, 2024, 24(3):171-176.
	JI L, YANG N, LIU W G, et al. Relationship between autonomic nervous function and cognitive function in elderly patients with Parkinson's disease[J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2024, 24(3):171-176. doi:10.3969/j.issn.1672-6731.2024.03.010.
[5]	马琳, 王樑, 赵彬芳, 等. 颅脑外伤患者围手术期Trx1、NGF、hs-CRP动态变化对预后的预测效能探讨[J]. 中国急救复苏与灾害医学杂志, 2023, 18(1):55-58.
	MA L, WANG L, ZHAO B F, et al. Predictive efficacy of the dynamic changes of Trx1,NGF and hs-CRP in patients with craniocerebral trauma during the perioperative period[J]. Chinese Journal of Emergency Recovery and Disaster Medicine, 2023, 18(1):55-58.
[6]	褚丽芳, 姚洁, 朱倩. 血清TSP-1、Trx1水平与脑梗死后认知功能障碍的关系[J]. 国际检验医学杂志, 2024, 45(3):353-357.
	CHU L F, YAO J, ZHU Q. The relationship between serum TSP-1 and Trx1 levels and cognitive dysfunction after cerebral infarction[J]. International Journal of Laboratory Medicine, 2024, 45(3):353-357. doi:10.3969/j.issn.1673-4130.2024.03.018.
[7]	樊瑞敏, 刘美香. 脑小血管病血清程序性细胞死亡因子4蛋白水平与认知功能障碍的相关性分析[J]. 安徽医药, 2023, 27(5):921-925.
	FAN R M, LIU M X. Correlation analysis of serum programmed cell death factor 4 protein level and cognitive dysfunction in cerebral small vessel disease[J]. Anhui Medicine, 2023, 27(5):921-925. doi:10.3969/j.issn.1009-6469.2023.05.015.
[8]	尚凤伟, 王瑞丽, 李海珍, 等. 血清AQP4、NFL、BAFF水平与癫痫患儿认知功能的相关性及其对认知功能损害的评估价值[J]. 海南医学, 2024, 35(10):1426-1430.
	SHANG F W, WANG R L, LI H Z, et al. Correlation between serum levels of AQP4,NFL and BAFF and cognitive function in children with epilepsy and their assessed value for cognitive impairment[J]. Hainan Medical Journal, 2024, 35(10):1426-1430. doi:10.3969/j.issn.1003-6350.2024.10.012.
[9]	白莹莹, 张红菊, 李中林, 等. 伴快速眼动睡眠期行为障碍的帕金森患者蓝斑下核与运动脑区功能连接的分析[J]. 中华医学杂志, 2019, 99(13):993-997.
	BAI Y Y, ZHANG H J, LI Z L, et al. Analysis of functional connectivity between the inferior locus and motor brain regions in Parkinson's patients with behavioral disorders during REM sleep[J]. Chinese Medical Journal, 2019, 99(13):993-997. doi:10.3760/cma.j.issn.0376-2491.2019.13.007.
[10]	中华医学会神经病学分会帕金森病及运动障碍学组, 中国医师协会神经内科医师分会帕金森病及运动障碍专业委员会. 中国帕金森病的诊断标准(2016版)[J]. 中华神经科杂志, 2016, 49(4):268-271.
	Parkinson's Disease and Motor Dyskinesia Group,Neurology Branch of Chinese Medical Association,Parkinson's Disease and Motor Disorders,Neurology Branch of Chinese Medical Doctor Association. Diagnostic criteria for Parkinson's disease in China(2016 version)[J]. Chinese Journal of Neurology, 2016, 49(4):268-271. doi:10.3760/cma.j.issn.1006-7876.2016.04.002.
[11]	SMITH T, GILDEH N, HOLMES C. The Montreal Cognitive Assessment:validity and utility in a memory clinic setting[J]. Can J Psychiatry, 2007, 52(5):329-332. doi:10.1177/070674370705200508.
[12]	孙洪吉, 谢越, 张晓红, 等. 蒙特利尔认知评估量表在健康体检人群中的应用[J]. 中华老年心脑血管病杂志, 2014, 16(2):174-177.
	SUN H J, XIE Y, ZHANG X H, et al. Application of the Montreal Cognitive Assessment Scale in a health examination population[J]. Chinese Journal of Elderly Cardiovascular and Cerebrovascular Diseases, 2014, 16(2):174-177. doi:10.3969/j.issn.1009-0126.2014.02.016.
[13]	曹利红, 张哲, 傅天. 帕金森病患者免疫球蛋白、Th9亚群水平变化及其与IGF-1、S-100B蛋白的相关性[J]. 中国免疫学杂志, 2024, 40(6):1248-1252.
	CAO L H, ZHANG Z, FU T. Changes in the levels of immunoglobulin and Th9 subsets and their correlation with IGF-1 and S-100B proteins in Parkinson's disease patients[J]. Chinese Journal of Immunology, 2024, 40(6):1248-1252. doi:10.3969/j.issn.1000-484X.2024.06.022.
[14]	JURCAU A, ANDRONIE-CIOARA F L, NISTOR-CSEPPENTO D C, et al. The involvement of neuroinflammation in the onset and progression of Parkinson's disease[J]. Int J Mol Sci, 2023, 24(19):14582. doi:10.3390/ijms241914582.
[15]	黄彦玮, 曾开泰, 温子琪, 等. 帕金森病的肠道菌群标志物研究进展[J]. 实用医学杂志, 2024, 40(11):1473-1478.
	HUANG Y W, ZENG K T, WEN Z Q, et al. Progress in intestinal microflora markers in Parkinson's disease[J]. Journal of Practical Medicine, 2024, 40(11):1473-1478. doi:10.3969/j.issn.1006-5725.2024.11.001.
[16]	卢洁. 重视PET成像在帕金森病认知功能障碍早期诊断的价值[J]. 中国医学影像学杂志, 2024, 32(3):209-212.
	LU J. Pay attention to the application of PET imaging in the early diagnosis of cognitive dysfunction in Parkinson's disease[J]. Chinese Journal of Medical Imaging, 2024, 32(3):209-212. doi:10.3969/j.issn.1005-5185.2024.03.001.
[17]	邢博真, 陈才伟, 符丽娜, 等. 血清Pref-1、Trx1与2型糖尿病患者认知功能障碍的关系[J]. 联勤军事医学, 2023, 37(9):778-782.
	XING B Z, CHEN C W, FU L N, et al. The relationship between serum Pref-1,Trx1 and cognitive dysfunction in patients with type 2 diabetes[J]. Joint Logistic Military Medicine, 2023, 37(9):778-782. doi:10.13730/j.issn.2097-2148.2023.09.011.
[18]	郭道骝, 钱燕群, 王枫, 等. 硫氧还蛋白1、活化T细胞趋化因子在脑梗死病人血清中的水平及与认知功能、预后的关系[J]. 安徽医药, 2024, 28(8):1603-1607.
	GUO D L, QIAN Y Q, WANG F, et al. Thioredoxin 1,the level of activated T cell chemokines in the serum of patients with cerebral infarction and the relationship with cognitive function and prognosis[J]. Anhui Medicine, 2024, 28(8):1603-1607. doi:10.3969/j.issn.1009-6469.2024.08.025.
[19]	LUNDBERG M, BOHMAN H, CURBO S, et al. Development of an ELISA displaying similar reactivity with reduced and oxidized human Thioredoxin-1(Trx1):the plasma level of Trx1 in early onset psychosis disorders[J]. J Immunol Methods, 2022, 510:113347. doi:10.1016/j.jim.2022.113347.
[20]	曹百慧. PDCD4在帕金森病中的作用、分子机制及其干预治疗[D]. 济南: 山东大学, 2023.
	CAO B H. The role,molecular mechanism of PDCD4 and its intervention in PD[D]. Ji'nan: Shandong University, 2023.
[21]	CAO G, KANG T, LI N, et al. Programmed cell death 4 blocks autophagy and promotes dopaminergic neuronal injury in Parkinson's disease[J]. Exp Ther Med, 2024, 27(4):135. doi:10.3892/etm.2024.12423.
[22]	冯娇娇, 邢雅杰, 刘丹丹, 等. AQP4、MMP-9及HMGB1预测癫痫患儿认知功能损害的价值分析[J]. 中国妇幼健康研究, 2023, 34(6):28-33.
	FENG J J, XING Y J, LIU D D, et al. Value analysis of AQP4,MMP-9 and HMGB1 in predicting cognitive impairment in children with epilepsy[J]. China Maternal and Child Health Research, 2023, 34(6):28-33. doi:10.3969/j.issn.1673-5293.2023.06.004.

组别	n	Trx1	PDCD4	AQP4
对照组	105	11.83±3.81	22.39±3.85	117.83±19.63
PD组	145	7.60±2.42	45.67±7.43	42.62±14.96
t		10.717^＊＊	29.367^＊＊	34.374^＊＊

组别	n	Trx1	PDCD4	AQP4
对照组	105	11.83±3.81	22.39±3.85	117.83±19.63
PD组	145	7.60±2.42	45.67±7.43	42.62±14.96
t		10.717^＊＊	29.367^＊＊	34.374^＊＊

组别	n	男性		年龄/岁		BMI/（kg/m²）		吸烟史		饮酒史		家族史		受教育年限/年		Hoehn-Yahr分期
组别	n	男性		年龄/岁		BMI/（kg/m²）		吸烟史		饮酒史		家族史		受教育年限/年		Ⅲ期		Ⅳ期		Ⅴ期
无CI组	102	54（52.94）		67.14±8.27		22.82±2.63		53（51.96）		57（55.88）		4（3.92）		12.39±1.37		35（34.31）		46（45.10）		21（20.59）
CI组	43	23（53.49）		67.47±8.41		21.63±2.21		22（51.16）		25（58.14）		2（4.65）		9.60±1.20		13（30.23）		13（30.23）		17（39.54）
χ²或t		0.004		0.218		2.603^＊		0.008		0.063		0.000		11.604^＊＊				5.938
组别	PD病程/ 年		MMSE 评分/分		MoCA 评分/分		TC/ （mmol/L）		TG/ （mmol/L）		LDL-C/（mmol/L）		HDL-C/（mmol/L）		Trx1/ （μg/L）		PDCD4/（μg/L）		AQP4/ （μg/L）
无CI组	4.34±1.26		27.37±1.21		27.81±1.28		4.71±1.35		1.56±0.51		2.65±0.47		1.41±0.35		8.31±2.34		43.39±5.87		47.54±14.83
CI组	5.86±1.52		20.21±2.53		21.37±2.55		4.89±1.38		1.64±0.55		2.73±0.53		1.49±0.41		5.92±1.67		51.08±7.96		30.98±6.35
t	6.231^＊＊		23.068^＊＊		20.225^＊＊		0.729		0.843		0.901		1.194		6.072^＊＊		6.454^＊＊		7.044^＊＊

组别	n	男性		年龄/岁		BMI/（kg/m²）		吸烟史		饮酒史		家族史		受教育年限/年		Hoehn-Yahr分期
组别	n	男性		年龄/岁		BMI/（kg/m²）		吸烟史		饮酒史		家族史		受教育年限/年		Ⅲ期		Ⅳ期		Ⅴ期
无CI组	102	54（52.94）		67.14±8.27		22.82±2.63		53（51.96）		57（55.88）		4（3.92）		12.39±1.37		35（34.31）		46（45.10）		21（20.59）
CI组	43	23（53.49）		67.47±8.41		21.63±2.21		22（51.16）		25（58.14）		2（4.65）		9.60±1.20		13（30.23）		13（30.23）		17（39.54）
χ²或t		0.004		0.218		2.603^＊		0.008		0.063		0.000		11.604^＊＊				5.938
组别	PD病程/ 年		MMSE 评分/分		MoCA 评分/分		TC/ （mmol/L）		TG/ （mmol/L）		LDL-C/（mmol/L）		HDL-C/（mmol/L）		Trx1/ （μg/L）		PDCD4/（μg/L）		AQP4/ （μg/L）
无CI组	4.34±1.26		27.37±1.21		27.81±1.28		4.71±1.35		1.56±0.51		2.65±0.47		1.41±0.35		8.31±2.34		43.39±5.87		47.54±14.83
CI组	5.86±1.52		20.21±2.53		21.37±2.55		4.89±1.38		1.64±0.55		2.73±0.53		1.49±0.41		5.92±1.67		51.08±7.96		30.98±6.35
t	6.231^＊＊		23.068^＊＊		20.225^＊＊		0.729		0.843		0.901		1.194		6.072^＊＊		6.454^＊＊		7.044^＊＊

项目	Trx1	PDCD4	AQP4
MMSE评分	0.478^＊＊	-0.338^＊＊	0.407^＊＊
MoCA评分	0.379^＊＊	-0.245^＊＊	0.436^＊＊